4.7 Article

Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies

期刊

INTERNATIONAL JOURNAL OF CANCER
卷 122, 期 11, 页码 2414-2421

出版社

WILEY
DOI: 10.1002/ijc.23412

关键词

telomere; minisatellite; recombination; ALT; PML-bodies

类别

资金

  1. Medical Research Council [G0500336] Funding Source: Medline
  2. MRC [G0500336] Funding Source: UKRI
  3. Medical Research Council [G0500336] Funding Source: researchfish

向作者/读者索取更多资源

Immortalized and cancer cells maintain their telomeres by activation of a telomere maintenance mechanism (TMM). In similar to 85% of cancers telomerase is activated (TA) but in some tumours, in particular sarcomas, an alternative lengthening of telomeres (ALT) pathway is used. Liposarcomas are the most common soft-tissue sarcoma in adults and they activate ALT or telomerase with equal frequency, however no TMM has been identified in similar to 50% of liposarcomas. In our study, we have shown that instability at the minisatellite MS32, usually associated with ALT activation, aids the identification of liposarcomas that have recombination-like activity at telomeres in absence of ALT associated PML-bodies (APBs). Furthermore, using single molecule telomere analysis, we have detected complex telomere mutations directly in ALT positive liposarcomas and interestingly in some liposarcomas with an unknown TMM but high MS32 instability. We have shown by sequence analysis that some of these complex telomere mutations must arise by an inter-molecular recombination-like process rather than by deletion caused by t-loop excision or by unequal telomere-sister-chromatid-exchange (T-SCE), which is known to be elevated in ALT cell lines. Preliminary evidence also suggests that inter-molecular recombination events may be processed differently in liposarcomas with APBs compared to those without. In conclusion, we have shown for the first time, that some telomerase negative liposarcomas without APBs have other features associ- ated with ALT, indicating that the incidence of ALT in these tumours has previously been under-estimated. This has major implications for the use of cancer treatments targeted at TMMs. (C) 2008 Wiley-Liss, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据